Skip to main content

Table 4 Univariable and multivariable analysis of factors associated with response to etanercept for polyarticular RF-negative and enthesitis-related JIA

From: Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Baseline characteristics Poor vs Intermediate and Excellent Responders Excellent vs Intermediate and Poor Responders
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Polyarticular RF-negative JIA
 Demographic
  Gender 0.886 (0.519-1.461) 0.642    1.334 (0.765-2.283) 0.295   
  Disease duration before start of etanercept 0.55 (0.312-0.917) 0.027 0.313 (0.116-0.730) 0.012 0.995 (0.573-1.818) 0.985   
  Age of disease onset 0.659 (0.391-1.087) 0.106 0.418 (0.176-0.866) 0.028 1.535 (0.84-3.14) 0.193 0.518 (0.267-0.945) 0.039
 Disease activity
  CHAQ score at start of etanercept 0.58 (0.321-0.984) 0.053 0.801 (0.300-2.108) 0.649 1.745 (0.982-3.255) 0.065 1.089 (0.469-2.543) 0.841
  VAS disease activity by patient/parent at start of etanercept 0.946 (0.565-1.562) 0.828    1.1 (0.617-1.934) 0.741   
  VAS disease activity by physician at start of etanercept 0.76 (0.436-1.266) 0.308    1.375 (0.785-2.444) 0.261   
  No. of joints with LOM 0.575 (0.328-0.96) 0.041 0.438 (0.150-1.129) 0.103 2.081 (1.069-4.712) 0.049 0.430 (0.185-0.900) 0.033
  Morning stiffness, min 0.505 (0.259-0.876) 0.026 0.524 (0.214-1.130) 0.121 4.592 (1.54-20.62) 0.021 0.680 (0.326-1.312) 0.267
 Previous therapy
  No. of DMARDs used before start of etanercept 0.638 (0.366-1.065) 0.095 1.272 (0.558-3.069) 0.573 0.707 (0.386-1.253) 0.243   
  Fact of biologics using before start of etanercept 0.696 (0.42-1.146) 0.155 0.604 (0.283-1.224) 0.170 0.891 (0.513-1.589) 0.685   
 Laboratory tests
  CRP at start of etanercept 0.712 (0.41-1.171) 0.189 0.658 (0.304-1.333) 0.252 3.361 (1.166-19.326) 0.088 0.539 (0.271-0.959) 0.046
Enthesitis-related JIA
 Demographic
  Gender - -    0.6 (0.242-1.365) 0.226   
  Disease duration before start of etanercept 0.17 (0.021-0.59) 0.029 3.980 (1.294-23.095) 0.048 3.219 (0.995-19.183) 0.12 0.385 (0.051-1.531) 0.263
  Age of disease onset 2.286 (0.885-7.397) 0.114    0.404 (0.13-1.002) 0.073 1.200 (0.308-5.023 0.789
 Previous therapy
  No. of DMARDs used before start of etanercept 0.737 (0.275-1.816) 0.51    3.587 (1.261-15.132) 0.039 0.351 (0.047-1.416) 0.205
  Fact of biologics using before start of etanercept 0.419 (0.161-0.997) 0.056 2.030 (0.714-6.369) 0.185 2.052 (0.81-8.276) 0.184 1.046 (0.220-4.252) 0.948
  1. All entries in italic are statistically significant